May 4, 2023

Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023

Visus CEO Ben Bergo presents Topline BRIO-I data at the JMP Securities Conference on Monday, May 15th. To register and view the live webcast, please click here.
CLICK TO CLOSE
Click to Open

illuminating
OUR MISSION

Visus Therapeutics™ is a clinical-stage pharmaceutical company lighting the way to dramatically improve patient lives through the development of differentiated, best-in-class ophthalmic therapies.

And we're just getting started...

DISCOVER OUR PIPELINE TODAY
Discover our pipeline today.

With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.

illuminating
OUR MISSION

Visus Therapeutics™ is a clinical-stage pharmaceutical company lighting the way to dramatically improve patient lives through the development of differentiated, best-in-class ophthalmic therapies.

And we're just getting started...

DISCOVER OUR PIPELINE TODAY
Discover our pipeline today.

With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.

Visus Therapeutics announce spositive Phase 2 Topline results for Investigational Brimichol [& Brimochol F] for the treatment of presbropia

LEARN MORE